Research

PIER

DRCR: Diabetic Retinopathy Clinical Research Network

HORIZON

SCORE – Phase III

SAILOR – Phase IIIb

 

Enrolling

View-1 – Phase III

 

Clinical research

Helping to create new knowledge is often a time consuming, meticulous and expensive endeavor. Nevertheless, it is through such efforts that care of patients improves and that is why the doctors and staff of Retina Consultants are actively involved in clinical research. We have participated in a number of investigations studying aspects of diabetic retinopathy and age-related macular degeneration. Trials investigating new treatments for these diseases are ongoing.

 


PIER – (Close-out only)

A Phase IIIb, multi-center, randomized, double-masked, sham injection-controlled study of the efficacy and safety of ranibizumab in subjects with subfoveal choroidal neovascularization with or without classic CNV secondary to AMD

Research Dates

December 2006–February 2007

Sponsor

Genentech

 

DRCR: Diabetic Retinopathy Clinical Research Network (12 Protocols)

Protocols involving diabetic eye diseases, i.e., diabetic retinopathy

Research Dates

December 2006–present

Sponsor

DRCR

 


HORIZON (FVF3426g) – Phase II

Phase III Open-Label Extension Study of Ranibizumab (Lucentis)

Research Dates

December 2006–present (three protocols enrolling)

Sponsor

Genentech

 

SCORE – Phase III

A multi-center, randomized Phase III trial designed to assess the efficacy and safety of standard care versus Triamcinolone Acetonide injection(s) for the treatment of macular edema associated with central retinal vein occlusion (CRVO)and branch retinal vein occlusion (BRVO)

Research Dates

December 2006–present

Sponsor

Emmes / NIH

 

SAILOR (FVF3689g) – Phase IIIb

Phase IIIb, single-masked, multicenter, randomized study to evaluate the safety and tolerability of ranibizumab in naïve and previously-treated patients with choroidal neovascularization (CNV) secondary to AMD.

Research Dates

December 2006–December 2007

Sponsor

Genentech

 

Actively enrolling

View-1 (VGFT-OD-0605) – Phase III

A randomized, double masked, active controlled phase III study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF trap in subjects with neovascular age-related macular degeneration

Research Dates

September 2007–present

Sponsor

Regeneron